tbuckley/cabot-search huggingface dataset:
Abstract 3894: Determination of the efficacious Entrectinib exposures required for pathway inhibition and anti-tumor activity in a subcutaneous and intracranial<i>TPM3-NTRK1</i>mutant tumor model
Authors: Cecile C. de la Cruz, Thomas Hunsaker, Faye Vazvaei, Dragomir Draganov, Li Yu, Mark Merchant
Journal: Cancer Research (2019)

Abstract Entrectinib is a selective and brain penetrant inhibitor with potency against TRKA, TRKB, TRKC, ROS1 and ALK currently in clinical development for the treatment of tumors harboring NTRK or ROS1 gene fusions. In multiple non-clinical models harboring NTRK or ROS1 gene fusions, entrectinib demonstrates potent tumor growth inhibition leading to tumor regressions. Entrectinib achieves exposure in the brain across multiple species with brain-to-plasma concentration ratios of 0.4 in mice, 0.6-1.5 in rats, and 1.4-2.2 in dogs after multiple oral administration. Previously Cook, et al. demonstrated that entrectinib demonstrates anti-tumor efficacy in a BCAN-NTRK1 glioma model, however only testing higher doses. Here we sought to better understand the effective exposures of entrectinib required for pathway inhibition and anti-tumor efficacy through dose-ranging efficacy, pharmacokinetics (PK) and pharmacodynamics (PD) studies using the TPM3-NTRK1 KM12-Luciferase (KM12-Luc) tumor model inoculated subcutaneously or intracranially. In the subcutaneous setting, entrectinib treatment results in significant dose-dependent inhibition of TRKA pathway signaling for up to 12 hours and anti-tumor activity with doses of 5 mg/kg (dosed orally (PO), every day (QD)) and above resulting in strong pathway suppression and tumor regressions. PK analysis demonstrated that an exposure of AUC24h of ≥20 µM.hr was associated with potent TRKA pathway inhibition and tumor growth inhibition. In the intracranial setting, entrectinib similarly demonstrated a dose-dependent effect on inhibition of tumor bioluminescence and enhanced animal survival. Pathway inhibition was observed at all doses of entrectinib with significant activity observed at doses of 5 mg/kg, PO, QD and above. In contrast to tumors inoculated subcutaneously, entrectinib doses of 15 mg/kg, PO, twice daily (BID) or 30 mg/kg, PO, QD were required to strongly inhibit anti-tumor efficacy with the highest dose of 60 mg/kg, PO, BID achieving full suppression of intracranial tumor growth. These data help to establish a model connecting entrectinib drug exposure in circulation and in the brain to pathway suppression and anti-tumor efficacy in an NTRK gene fusion tumor model, which support clinical use of entrectinib in patients with brain NTRK or ROS1 gene fusion tumors. Citation Format: Cecile C. de la Cruz, Thomas Hunsaker, Faye Vazvaei, Dragomir Draganov, Li Yu, Mark Merchant. Determination of the efficacious Entrectinib exposures required for pathway inhibition and anti-tumor activity in a subcutaneous and intracranialTPM3-NTRK1mutant tumor model [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2019; 2019 Mar 29-Apr 3; Atlanta, GA. Philadelphia (PA): AACR; Cancer Res 2019;79(13 Suppl):Abstract nr 3894.
Metoclopramide treatment of tardive dyskinesia
Authors: J. M. Karp
Journal: JAMA (1981)

Five patients with tardive dyskinesia (average age, 64 years) were treated with a central dopamine blocking agent, metoclopramide hydrochloride. The duration of symptoms ranged from four to 30 months. A pretreatment disability score was graded (0 to 4) for buccolingual, extremity, and truncal movements and for duration of tongue protrusion. A 59% improvement was achieved in total disability scores. Tongue protrusion demonstrated the most noticeable improvement. The average daily dosage ranged from a minimum of 20 mg to a maximum of 80 mg given in divided doses. Duration of follow-up ranged from three to eight months. Preliminary data suggest that metoclopramide may be effective in the treatment of tardive dyskinesia. (<i>JAMA</i>1981;246:1934-1935)
Liver cancer: Pathogenesis and treatment
Authors: Jeffrey Mccombs, Xiaodan Zhang, Teresa Mettler, William Harmsen, W Kim, Terry Therneau, Lewis Roberts, Roongruedee Chaiteer- Akij
Journal: Hepatology (2013)

erans Health Administration.Our results use a large, real-world sample of HCV patients to verify earlier findings that viral load reduction through treatment can significantly reduce the risk of adverse patient outcomes in HCV patients.
Quick Uptakes...
Authors: Rebecca Voelker
Journal: JAMA (1997)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Birth Control in Comprehensive Health Care
Journal: JAMA (2014)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Posterior circulation ischaemic stroke
Journal: BMJ (2014)

In the first sentence of the section "What treatment is recommended after posterior circulation stroke?" the blood pressure target should have read "less than 140 mm Hg/80 mm Hg," rather than "less than 80 mm Hg/140 mm Hg."Secondly, in the table, along the "Quadrantanopia" row it should have read + under the "Anterior circulation" column and ++ under the "Posterior circulation" column.
Tuberculin Conversion
Authors: David T. Smith
Journal: JAMA (1967)

<h3>To the Editor:—</h3> I have read with great interest Dr. Ochs' report on tuberculin conversions in naval personnel on board the USS<i>Long Beach</i>in 1962 and 1963 (<b>200</b>:1019, 1967). It is obvious from Dr. Ochs' article that he was disturbed to find that 9% of approximately 1,000 crew members converted from a negative reaction to the 5-TU, intermediate dose of PPD ( 0.0001 mg), to a positive reaction to the same dose, when the tests were repeated later. A conversion rate of 9% per annum was indeed shocking when he was expecting an annual conversion rate of one fourth of 1%. Furthermore, no symptoms of disease developed in any of these converters, and physical examination and x-ray studies showed no evidence of disease. Dr. Ochs suggests, "The conversions may have been related to 'naturally occurring' atypical mycobacteria in the geographic area. The ship was berthed at the ports of
Differing patterns of stent edge restenosis with differing forms of brachytherapy Marco Zimarino, Neil J. Weissman, Ron Waksman, Raffaele De Caterina, Javied M. Ahmed, Augusto D. Pichard, Gary S. Mintz. Washington Hospital Center, Washington, DC, Univ of Chieti, Chieti, Italy
Journal: Journal of the American College of Cardiology (2001)
THE ATLANTA MEETING.
Journal: JAMA (1896)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
NATIONAL CANCER INSTITUTE MONOGRAPHS
Journal: JNCI Journal of the National Cancer Institute (1988)

Journal Article NATIONAL CANCER INSTITUTE MONOGRAPHS Get access JNCI: Journal of the National Cancer Institute, Volume 80, Issue 19, 7 December 1988, Page 1582, https://doi.org/10.1093/jnci/80.19.1582 Published: 07 December 1988
THE CHAOS OF INSTITUTIONAL DRUG THERAPY AND MANAGEMENT OF PATIENTS
Journal: JAMA (1929)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
HBsAg relapse after living donor liver transplantation in hepatocelluler carcinoma patients with hepatitis D virus infection may result in hepatocellular carcinoma relapse
Authors: Adil Baskiran, Tevfik Tolga Sahin, Volkan Ince, Serdar Karakas, Fatih Ozdemir, Ipek Balikci Cicek, Kendal Yalcin, Brian Carr, Sezai Yilmaz
Journal: Journal of Hepatology (2020)
A Blood Heater for Use in Transfusion
Journal: JAMA (1963)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Prepayment for Medical Care
Authors: Cecil G. Sheps, Daniel L. Drosness
Journal: New England Journal of Medicine (1961)

Gaps in EnrollmentDespite the growth of prepayment, not all segments of the population are enrolled equally for health care under insurance. There are three important enrollment gaps: the rural population; the lower-income group; and the aged.Rural PopulationA recent study of enrollment in rural areas divided the states by the preponderance of rural population.17 The rural character of a population was indicated by the percentage of total population that was rural‡ in 1950. It was found that in states whose population was less than 40 per cent rural, over three quarters of the people had some form of . . .
Regional Variation in Hip Fracture: Is It due to Increased Milk Consumption in the North, 50 Years Ago?-Reply
Authors: Steven J. Jacobsen
Journal: JAMA (1990)

<h3>In Reply.—</h3> Dr Bierlein makes a good point that the decreased incidence of hip fracture in the North is striking, with historical milk and milk product consumption providing an attractive etiologic hypothesis. As we mentioned, however, good data with which to test this hypothesis are, to our knowledge, lacking. We have, however, been able to locate state-specific milk production data dating back to 1909.<sup>1</sup>These data show that of an estimated 7.5 million gallons of milk produced, 3.2 million gallons was produced in the East North Central and West North Central census divisions, and an additional 1.3 million gallons was produced in the Middle Atlantic states. The South Atlantic, East South Central, and West South Central combined to produce an estimated 1.5 million gallons of milk. While these data are suggestive, the association is tenuous at best. Data on milk production may not necessarily reflect milk consumption. For example,
New York State Medical Association.
Journal: JAMA (1884)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
SUGAR CONSUMPTION, SUPPLY AND DEMAND
Journal: JAMA (1930)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Metastatic adrenal cortical carcinoma. Prolonged regression with mitotane therapy
Authors: J. Jarabak
Journal: JAMA (1981)

CURRENTLY, there is a disagreement concerning the effectiveness of mitotane (o,p'-DDD) (1,1-dichloro-2-[o-chlorophenyl]-2-[p-chlorophenyl]-ethane) in the therapy for metastatic adrenal cortical carcinoma. Following the initial favorable report,<sup>1</sup>measurable tumor response was observed in two large series in 34 %<sup>2</sup>and 61 %<sup>3</sup>of patients treated with this drug, and overall survival was prolonged when compared with an earlier group of untreated persons whose mean survival was 2.9 months. However, in another series,<sup>4</sup>survival was not improved. The following case is presented to illustrate a long-term remission of adrenocortical carcinoma and the effects that have been associated with the ingestion of more than 13 kg of mitotane. <h3>Report of a Case</h3> A 49-year-old woman was admitted to a hospital in November 1967 with hirsutism and masses in the left breast and abdomen. Roentgenograms disclosed metastases in the ribs and liver and downward displacement of the left kidney. Two 24-hour urine collections
NECROLOGY.
Authors: G. W. Davis
Journal: JAMA (1896)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Lupus foot.
Authors: K D Morley, A Leung, R I Rynes
Journal: BMJ (1982)

Treatment of ethylene glycol poisoning with peritoneal dialysisEthylene glycol is commonly available as a constituent of antifreeze solutions and is itself non-toxic.Since, however, the ingestion of over about 100 ml ethylene glycol (1 8 mol; 110 g) in an adult is potentially lethal owing to the production of toxic metabolites, treatment with an inhibitor of ethylene glycol metabolism, of which ethanol is the most convenient, should be started as soon as is practicable.Peritoneal dialysis or haemodialysis is also indicated to enhance the elimination of unchanged ethylene glycol and possibly also its metabolites, especially since renal impairment is one of the first serious mani- festations of poisoning with this compound.There have been few reports1 5 of the use of dialysis in such cases, however, and the amount of ethylene glycol recovered was calculated in only two patients, one a child treated with peritoneal dialysis4 and one an adult treated with Details of three patienits poisoned with ethylene glycol and treated with peritoneal dialysis Amount of Approximate Pre-dialysis Duration of ethylene glycol Renal excretion Case Age (years) amount of ethylene glycol
Experimental alterations in gastric mucosal cellular population in dogs
Authors: W. P. Ritchie
Journal: JAMA (1966)

Although the pathophysiology of peptic ulcer is complex and its etiology obscure, it seems clear that the presence of acid is essential to the development of this disease entity. While hypersecretion of hydrochloric acid is not invariably encountered clinically, it is significant that the highest levels of acid secretion ever recorded have been found in patients with the Zollinger-Ellison syndrome, certainly the most virulent form of the peptic ulcer diathesis extant. In 1960, Card and Marks<sup>1</sup>demonstrated that a direct relationship existed between the maximal secretory ability of the canine stomach and its parietal cell population. The subsequent communication of Polacek and Ellison<sup>2</sup>in 1963, showing that the number of parietal cells was increased an average of threefold in patients with duodenal ulcer and eightfold in those with the Zollinger-Ellison syndrome, suggests that one of the basic mechanisms of peptic ulceration may be an overabundance of gastric acid
Methodologic Research Needs in Environmental Epidemiology: Data Analysis
Authors: Ross L. Prentice, Duncan Thomas
Journal: Environmental Health Perspectives (1993)

A brief review is given of data analysis methods for the identification and quantification of associations between environmental exposures and health events of interest.Data analysis methods are outlined for each of the study designs mentioned, with an emphasis on topics in need of further research.Particularly noted are the need for improved methods for accommodating exposure assessment measurement errors in analytic epidemio- logic studies and for improved methods for the conduct and analysis of aggregate data (ecologic) studies.-Environ Health Perspect 101 (Suppl 4): 39-48 (1993).